Oncology and Hematology

17-32 of 74

• 

  RestartResume

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  RestartResume

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  MinuteCE®

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  Douglas Adkins, MD

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  0.75 program credits

• 

  RestartResume

  Applying Perioperative ICIs in Clinical Practice

  RestartResume

  Applying Perioperative ICIs in Clinical Practice

  MinuteCE®

  Applying Perioperative ICIs in Clinical Practice

  Douglas Adkins, MD

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  0.75 program credits

• 

  RestartResume

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  RestartResume

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  MinuteCE®

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  Douglas Adkins, MD; Ravindra Uppaluri, MD, PhD

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  • 

    

    Ravindra Uppaluri, MD, PhD

  • 

    

    Nancy Lee, MD, FASTRO

  0.75 program credits

• 

  MinuteCE®

  Advancing Care in Locally Advanced HNSCC: Integrating Perioperative Immunotherapy and Multimodal Strategies

  Douglas Adkins, MD; Ravindra Uppaluri, MD, PhD

  0.75 credits 7 episodes

  • 

    

    Douglas Adkins, MD

  • 

    

    Ravindra Uppaluri, MD, PhD

  • 

    

    Nancy Lee, MD, FASTRO

  0.75 credits 7 episodes

• 

  RestartResume

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  RestartResume

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  MinuteCE®

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  Ravindra Uppaluri, MD, PhD

  0.75 program credits

  • 

    

    Ravindra Uppaluri, MD, PhD

  0.75 program credits

• 

  MinuteCE®

  Breaking Barriers in AML: Risk Stratification, Molecular Profiling, and Novel Menin-Directed Treatment Options

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 credit 10 episodes

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  MinuteCE®

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  MinuteCE®

  Managing Adverse Events Associated With Menin Inhibitors 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  MinuteCE®

  Stratifying Risk to Guide Therapy in R/R AML 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  MinuteCE®

  Menin Inhibitors: Biologic and Clinical Rationale 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  RestartResume

  Emerging Directions in Menin-Directed AML Therapy 

  MinuteCE®

  Emerging Directions in Menin-Directed AML Therapy 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Expert Recommendations and Key Takeaways

  RestartResume

  Expert Recommendations and Key Takeaways

  MinuteCE®

  Expert Recommendations and Key Takeaways

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  MinuteCE®

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  RestartResume

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  MinuteCE®

  Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Applying Evidence to Clinical Practice 

  RestartResume

  Applying Evidence to Clinical Practice 

  MinuteCE®

  Applying Evidence to Clinical Practice 

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  RestartResume

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  MinuteCE®

  Molecular Profiling as a Cornerstone of Precision AML Therapy

  Ghayas Issa, MD; Amir Fathi, MD

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit